论文部分内容阅读
目的 初步探讨口服Ⅱ型胶原 (CⅡ )治疗类风湿关节炎的疗效和安全性。方法 用随机双盲和安慰剂对照的方法 ,70例活动性类风湿关节炎患者随机分为试验组和对照组各 3 5例 ,分别口服Ⅱ型胶原每日0 1mg和安慰剂 ,随访 12周 ,比较观察二组的疗效 ,并记录不良反应。结果 用药 12周 ,有效率试验组和对照组分别为 54 55%和 12 12 % (P <0 0 1) ,显效率两组分别为 18 18%和 3 13 % (P <0 0 1) ,试验组明显高于对照组 ;口服CⅡ治疗有效患者的病程明显短于无效患者 ;两组不良反应表现为轻度可耐受的胃肠道反应 ,试验组和对照组发生率分别为 15 15%和 12 50 % ,差异无显著性。结论 口服Ⅱ型胶原蛋白治疗类风湿关节炎安全有效 ,不良反应轻 ,发病早期使用可提高有效率。
Objective To investigate the efficacy and safety of oral administration of type Ⅱ collagen (C Ⅱ) in the treatment of rheumatoid arthritis. Methods A randomized, double-blind and placebo-controlled trial of 70 active rheumatoid arthritis patients was randomly divided into experimental group and control group, 35 cases each. Type Ⅱ collagen was administered orally daily at 0.1 mg and placebo for 12 weeks The curative effects of the two groups were observed and the adverse reactions were recorded. Results After 12 weeks of treatment, the effective rate was 54 55% in the test group and 12 12% in the control group (P <0.01). The effective rates in the two groups were 18 18% and 31 3% (P 0 01), respectively The experimental group was significantly higher than the control group; oral C Ⅱ treatment of patients with significantly shorter duration of disease than ineffective patients; two adverse reactions showed mild tolerable gastrointestinal reactions, test group and control group were 15 15% And 12 50%, the difference was not significant. Conclusion Oral administration of type Ⅱ collagen is safe and effective in the treatment of rheumatoid arthritis with mild side effects and early onset of disease can improve the efficiency.